Skip to main content
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. — Investor Relations & Filings

Ticker · TPST ISIN · US69014Q1013 US Professional, scientific and technical activities
Open in API
Filings indexed 985 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country US United States of America
Listing US TPST

About Tempest Therapeutics, Inc.

https://www.tempesttx.com/

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-06-01 English
8-K
Board/Management Information Classification · 92% confidence The document is a Form 8-K current report filed pursuant to the Securities Exchange Act, specifically Item 5.02 covering the resignation of a board director and related compensatory arrangements. This clearly corresponds to an announcement of changes in the company’s board of directors or senior management. Therefore, it should be classified under Board/Management Information.
2026-05-29 English
8-K
Delisting Announcement Classification · 98% confidence The document is a Form 8-K “Current Report” filed under the Exchange Act, and specifically Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard (Nasdaq deficiency letter regarding stockholders’ equity and independent director requirements). This is clearly a delisting‐related announcement, matching the “Delisting Announcement” category (Code: DLST).
2026-05-22 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed under Item 5.02 announcing the resignation of multiple board members and the related separation agreements. This is a corporate notification of changes in the company’s board of directors. Such filings are classified as Board/Management Information (MANG).
2026-05-22 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K
Earnings Release Classification · 92% confidence The document is a Form 8-K current report under Item 2.02 (“Results of Operations and Financial Condition”) providing a press release with the company’s quarterly financial results for the period ended March 31, 2026. This is the initial announcement of quarterly financial results, which fits the definition of an Earnings Release (ER). Q1 2026
2026-05-14 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.